Hoth Therapeutics, Inc. (HOTH) Tuesday announced promising preclinical results for its investigational Alzheimer's drug, HT-ALZ. The company's shares were rising more than 15 percent in pre-market.
In the study, Alzheimer's model mice treated with HT-ALZ showed fewer reactive astrocytes compared to vehicle-treated group. Astrocytes, star-shaped cells found in the nervous system, become reactive in response to virtually all pathological conditions in the central nervous system. They play a role in the progression of neurodegenerative diseases like Alzheimer's. In a recent study using Alzheimer's model mice treated with varying doses of HT-ALZ, significant reductions in astrocyte activity were observed in key areas of the brain, suggesting a potential link between reduced reactive astrocytes, and improved cognitive function, the company said in a statement.
"The reductions in astrocyte activity and the corresponding improvements in cognitive function observed with HT- ALZ give us confidence as we move forward in our development process," said Robb Knie, CEO of Hoth.
Hoth Therapeutics stock had closed at $1.01, down 8.18 percent on Monday. It has traded in the range of $0.5800 - $1.7900 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.